Tarsons Products Limited · NSE:TARSONS

Tarsons Products — Q4 FY2022 Earnings Presentation

32 slides from Tarsons Products's earnings presentation, May 28, 2022

  1. Slide 1: Cover letter to stock exchanges

    An ISO 9001 & ISO 13485Certified Company Date: 28th May, 2022 To, To, The Manager The Manager listing Department listing Department BSELimited, National Stock Exchange of India Limited, Phiroze Jee Jee Bhoy Towers, Exchange Plaza, 5th Floor, Plot No. C/1, Dalal Street, G Block, Bandra - Kurla Comple

  2. Slide 2: Tarsons Products Limited Investor Presentation - May 2022

    TARSONS PRODUCTS LIMITED Investor Presentation - May 2022 Leading player in the domestic plastic labware market and presence over 40 countries across the Globe

  3. Slide 3: Safe Harbor

    Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu

  4. Slide 4: Tarsons – at a Glance

    Tarsons – at a Glance One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments) Products used in laboratories across research organizations, academia institutes, pharm

  5. Slide 5: Our Journey

    Our Journey Acquired 5 acres of land in Panchla & 6 acres of land in Amta to develop another facility for capacity Incorporation of TPPL Expanded product line by Became an ISO 9001 Obtained ISO 13485:2016/NS- expansion, introduction of new with manufacturing of initiating manufacturing certified man

  6. Slide 6: Leading Indian Labware Supplier

    Leading Indian Labware Supplier Ability to offer differentiated, user friendly, Trusted Brand for high quality Expertise in production of a wide range of reliable quality & cost-effective products products in the plastic labware market labware products & amongst the top has enabled strong brand with

  7. Slide 7: Our Competitive Edge

    Our Competitive Edge Geographical Presence Brand & Quality Wide geographic reach through a Leading Indian supplier to the life sciences strong sales & distribution network sector with strong brand recognition and high- quality diversified products across varied customer segments. 03 04 State of Art

  8. Slide 8: Catering to diversified End User Industry

    Catering to diversified End User Industry… Measures to strengthen customer relations Regular Feedback from Customers on quality, Academic Institutes & National Centre for Indian Institute of Rain Forest KIIT 1 delivery & cost Biological Sciences Chemical Technology Research Institute University Rese

  9. Slide 9: Our State-of-the-art Manufacturing Facilities

    Our State-of-the-art Manufacturing Facilities… Key Highlights of the High Precision Manufacturing Process ✓ Vertically integrated manufacturing capabilities with design & development being carried out in-house ✓ Automated manufacturing with use of robotics & other technologies developed in collabora

  10. Slide 10: Widespread Domestic Sales & Distribution network

    …with widespread Domestic Sales & Distribution network… Comprehensive Pan-India Distribution Network Long-standing relationships with Distributors North: 20% of FY22 Domestic Sales East: 19% of FY22 Domestic Sales 42 Distributors 42 Distributors West: 23% of FY22 Domestic Sales 18 Distributors South

  11. Slide 11: Huge Export Market Potential

    …with huge underlying Export Market Potential… Huge Export Opportunity Market One of the very few players to have a Global Reach ✓ As of 31st March 2022, the company sold its products to 40+ countries via 45+ distributors Demand for plasticware expected to grow at ✓ Export operations are a blend of

  12. Slide 12: Offering Wide Range of High-Quality Products

    …offering Wide Range of High-Quality Products… Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachables Consumables Reusables Others 63% of FY22 33% of FY22 4% of FY22 Revenues Revenues Revenues • Portfolio of

  13. Slide 13: Consumables (63% of FY22 Sales)

    …diversified product portfolio of Plastic Labware Pipette Tips Centrifuge Tubes Petri Dishes Cryo Vials Storage Vials Consumables (63% of FY22 Sales) Perfect for versatile applications, • Mostly used in the culture of Used for storage of biological Storage vials are designed for use Mostly used in r

  14. Slide 14: Glimpse of our product portfolio & processes

    Glimpse of our product portfolio & processes Video link – Click here Video link – Click here Video link – Click here Video link – Click here Video link – Click here For more information & videos please visit www.tarsons.com/video-new 13

  15. Slide 15: Key Business Strategies

    Key Business Strategies • Focus on branding & promotion to enhance visibility in the labware industry to increase brand awareness & loyalty • Manufacture New Products in the cell culture & robotic handled consumables and expand Enhance existing & expand into the import dominated markets of these pro

  16. Slide 16: Experienced Board of Director & Managerial Team

    Experienced Board of Director & Managerial Team Gaurav Podar Sanjive Sehgal Non-Executive Nominee Director Chairman & Managing Director • Currently, Director with ADV Partners • Chairman & Managing Director of Tarsons Product • Investment professional with 10+ years of experience Limited • Has over

  17. Slide 17: Contribution towards Environmental, Social & Governance

    Contribution towards Environmental, Social & Governance Clean room conditions Use of Medical Grade eliminates all chances of NO litigations faced for pollution contamination Plastics. Products are designed to or degradation of environment withstand critical use over the past five years Productivity

  18. Slide 18: Industry Update

    DELIVERING TRUST

  19. Slide 19: Plastic Labware Market

    Plastic Labware Market Indian plastic labware market is expected to grow at 16% CAGR from 2020-2025 Split of Global Market Size of Plastic Labware (2020) Certrifuge Global Laboratory Equipment Market Indian Laboratory Equipment Market ware ▪ Centrifuge & Liquid Handling market Size (INR Bn) Size (IN

  20. Slide 20: Rapid Shift from Glassware to Plasticware in India

    Rapid Shift from Glassware to Plasticware in India Indian Laboratory Equipment Market (Breakup of Glassware and Plasticware segments) INR 10.8 bn INR 11.3 bn INR 8.4 bn Key reasons for the shift: Market Size INR 7.5 bn INR 12.2 bn INR 25.8 bn ▪ Increased Applicability: Superior ability to handle rad

  21. Slide 21: Q4 & FY22 Financial Highlights

    Q4 & FY22 Financial Highlights

  22. Slide 22: Q4 & FY22 Key Financial Highlights

    Q4 & FY22 Key Financial Highlights REVENUE (in Rs. Crs) EBITDA (in Rs. Crs) PAT (in Rs. Crs) +31% +48% +46% 301 153 101 229 103 69 +26% +27% +25% 85 44 24 29 68 35 Q4FY21 Q4FY22 FY21 FY22 Q4FY21 Q4FY22 FY21 FY22 Q4FY21 Q4FY22 FY21 FY22 GP Margin EBITDA Margin PAT Margin 76.5% 77.7% 79.1% 51.6% 52.2%

  23. Slide 23: Q4 & FY22 Key Operational Highlights

    Q4 & FY22 Key Operational Highlights Revenue Spilt – Products Revenue Spilt – Domestic : Export FY21 FY22 +26% +31% 85 301 5% 4% 68 229 60 202 34% 33% 49 23.7% 153 31.4% 61% 63% 25 76 99 19 30.9% 31.3% Q4FY21 Q4FY22 FY21 FY22 Consumables Reusables Others Domestic Exports ➢ Domestic revenues for Q4FY

  24. Slide 24: Q4 & FY22 Consolidated Profit & Loss Statement

    Q4 & FY22 Consolidated Profit & Loss Statement Profit and Loss (in Rs. Crs) Q4FY22 Q4FY21 YoY Q3FY22 Q-o-Q FY22 FY21 YoY Revenue from Operations 84.9 67.6 25.7% 70.7 20.2% 300.8 228.9 31.4% Cost of Goods Solds 19.0 15.9 15.6 62.9 61.5 Gross Profit 66.0 51.7 27.6% 55.1 19.8% 237.9 167.4 42.1% Gross P

  25. Slide 25: Management Commentary

    Management Commentary Commenting on the Q4 & FY22 performance of the company Mr. Rohan Sehgal Said: “We finished the year on a high note, with strong revenue and profit growth for FY22 as a result of improved product mix and operational efficiencies. Revenue grew by 31% and PAT grew by 46% for FY22

  26. Slide 26: Historical Consolidated Financial Highlights

    Historical Consolidated Financial Highlights REVENUE (in Rs. Crs) EBITDA (in Rs. Crs) PAT (in Rs. Crs) +31% 301 153 101 +48% +58% 229 103 69 176 69 41 FY20 FY21 FY22 FY20 FY21 FY22 FY20 FY21 FY22 GP Margin EBITDA Margin PAT Margin 676 bps 1,139 bps 1,042 bps 79.1% 50.8% 33.5% 72.3% 73.1% 45.2% 30.1%

  27. Slide 27: Historical Consolidated Profit & Loss Statement

    Historical Consolidated Profit & Loss Statement Profit and Loss (in Rs. Crs) FY22 FY21 FY20 CAGR Revenue from Operations 300.8 228.9 175.9 30.8% Cost of Goods Solds 62.9 61.5 48.7 Gross Profit 237.9 167.4 127.2 36.7% Gross Profit Margin 79.1% 73.1% 72.3% 676 bps Employee Cost 31.4 24.4 20.1 Other Ex

  28. Slide 28: Historical Consolidated Balance Sheet

    Historical Consolidated Balance Sheet Assets (in Rs. Crs) Mar-22 Mar-21 Mar-20 Equity & Liabilities (in Rs. Crs) Mar-22 Mar-21 Mar-20 Non - Current Assets 299.7 183.1 128.9 Total Equity 489.9 244.3 197.6 Property Plant & Equipment's 181.4 113.7 87.6 Share Capital 10.6 0.2 0.2 CWIP 32.2 21.5 19.3 Oth

  29. Slide 29: Historical Consolidated Cash Flow Statement

    Historical Consolidated Cash Flow Statement Particulars (in Rs. Crs) FY22 FY21 FY20 Net Profit Before Tax 135.0 92.4 53.1 Adjustments for: Non -Cash Items / Other Investment or Financial Items 23.7 15.8 20.0 Operating profit before working capital changes 158.7 108.2 73.1 Changes in working capital

  30. Slide 30: Key Ratios

    Key Ratios Return on Equity Return on Capital Employed Return on Asset Debt to Equity 28.2% 34.3% 23.3% 0.2 25.4% 27.2% 18.5% 0.1 20.5% 20.6% 16.3% 0.0 FY20 FY21 FY22 FY20 FY21 FY22 FY20 FY21 FY22 FY20 FY21 FY22 Current Ratio Working Capital (in Rs. Crs) Working Capital Days* Asset Turnover 7.0 209.

  31. Slide 31: Key Takeaways

    Key Takeaways Leading Indian manufacturer of Financial profile with 45%+ EBITDA labware with an established brand & margins & 30%+ ROCE coupled with focus on high-quality products double-digit growth rates Presence in an industry with double- Highly automated state-of-the-art digit growth potential

  32. Slide 32: Thank You

    Thank You Tarsons Products Limited Strategic Growth Advisors Private Limited CIN: L51109WB1983PLC036510 CIN: U74140MH2010PTC204285 Mr. Santosh Agarwal – Chief Financial Officer Mr. Sagar Shroff/Mr. Pratik Shah santosh@tarsons.in sagar.shroff@sgapl.net / p.s.shah@sgapl.net +91 98205 19303 / +91 98700

Tarsons Products — Q4 FY2022 Earnings Presentation on 6ix